Last reviewed · How we verify
VH4004280 Formulation E — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
VH4004280 Formulation E (VH4004280 Formulation E) — ViiV Healthcare.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| VH4004280 Formulation E TARGET | VH4004280 Formulation E | ViiV Healthcare | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- VH4004280 Formulation E CI watch — RSS
- VH4004280 Formulation E CI watch — Atom
- VH4004280 Formulation E CI watch — JSON
- VH4004280 Formulation E alone — RSS
Cite this brief
Drug Landscape (2026). VH4004280 Formulation E — Competitive Intelligence Brief. https://druglandscape.com/ci/vh4004280-formulation-e. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab